[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Liaquat University of Medical & Health Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":308},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,40,65,88,111,133,154,175,196,219,242,263,288],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100644981","colipral-probiotic-strain-escherichia-coli-5c-ecp24-for-prevention-of-recurrent-cystitis-in-menopausal-women-100644981",false,"NCT07676604","Colipral® (Probiotic Strain Escherichia Coli 5C (ECP24®)) for Prevention of Recurrent Cystitis in Menopausal Women","Study to Evaluate the Efficacy and Safety of Colipral® (Probiotic Strain Escherichia Coli 5C (ECP24®)) in the Prevention of Recurrent Cystitis in Menopausal Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Menopausal female patients.\n* Age between 55 and 70 years.\n* Diagnosis of recurrent cystitis: ≥2 episodes in 6 months or ≥3 episodes in 12 months, with at least 1 documented episode from urine culture in the last 12 months (if available).\n\nExclusion Criteria:\n\n* Complicated urinary tract infections (UTIs) or major complicating factors, including relevant anatomical abnormalities, catheterization, active calculosis, or significant immunosuppression.\n* Hormone replacement therapy (HRT) that has been ongoing or discontinued for less than 6 months.\n* Pyelonephritis within the past 6 months.\n* Ongoing continuous antibiotic prophylactic therapy (or inability to suspend it).\n* Chronic inflammatory bowel diseases (ulcerative colitis or Crohn's disease).\n* Allergy to the probiotic or its excipients.","FEMALE","55 Years","70 Years",{"count":20,"type":21},134,"ESTIMATED","INTERVENTIONAL",[24],"NA","Recurrent cystitis is a common condition in menopausal women and is associated with impaired quality of life and increased antibiotic use. This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of Colipral® in preventing recurrent cystitis in menopausal women. Participants will be randomized to receive either Colipral® (probiotic strain Escherichia coli 5C (ECP24®)))or placebo for 12 weeks and will be followed for a total of 24 weeks. The study will assess the occurrence of symptomatic cystitis recurrences confirmed by urine culture, as well as symptoms, quality of life, urinary pain, and antibiotic consumption.",[27],"Recurrent Cystitis","NOT_YET_RECRUITING","2026-07-01",{"date":31,"type":32},"2026-07-02","ACTUAL",{"date":34,"type":21},"2027-07-06",{"date":36,"type":21},"2027-07-31",{"name":38,"class":39},"Liaquat University of Medical & Health Sciences","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100641471","assessment-of-the-efficacy-of-a-highly-standardized-ginger-and-perilla-nutraceutical-dispepril-in-improving-gastric-and-intestinal-symptoms-in-patients-with-functional-dyspepsia-100641471","NCT07655219","Assessment of the Efficacy of a Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia","Assessment of the Efficacy of a Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia: A Multicenter, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n* Male or female participants aged 18 to 65 years\n* Diagnosis of functional dyspepsia according to Rome IV criteria\n* Willingness and ability to provide written informed consent\n* Ability to follow study product administration instructions\n* Ability to attend scheduled study visits\n\nExclusion Criteria:\n\n* Gastrectomy\n* Cancer\n* Use of NSAIDs, cholagogues, or tricyclic antidepressants within 30 days prior to enrollment\n* Helicobacter pylori positivity\n* Alcoholism or other substance abuse\n* Hepatic disease\n* Renal disease\n* History of hypersensitivity to formulation active ingredients or excipients\n* Pregnancy or breastfeeding\n* Participation in another clinical trial or completion of another clinical trial within 1 month prior to enrollment\n* Refusal or inability to provide informed consent","ALL","18 Years","65 Years",{"count":51,"type":21},400,[24],"This multicenter, prospective, randomized, controlled clinical trial aims to evaluate the efficacy of a nutraceutical treatment containing highly standardized extracts of ginger (Zingiber officinale) and perilla (Perilla frutescens) (Dispepril®, Pharmextracta S.p.A. Pontenure, Italy) in improving gastric and intestinal symptoms in adults with functional dyspepsia. The study will assess the non-inferiority of Dispepril® compared with standard proton pump inhibitor (PPI) therapy in reducing postprandial distress symptoms. Participants will be randomized in a 2:1:1 ratio to receive Dispepril® alone, Dispepril® plus half-dose PPI, or full-dose PPI for 14 days. Efficacy will be assessed using the Leuven Postprandial Distress Scale (LPDS), together with evaluations of treatment tolerability, adherence, and adverse events.",[55],"Functional Dysphonia","2026-06-15",{"date":58,"type":32},"2026-06-17",{"date":60,"type":21},"2026-06-22",{"date":62,"type":21},"2026-11-30",{"name":38,"class":39},4,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":47,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100634208","co-supplementation-with-bifidobacterium-longum-w11-and-colopectin-for-maintenance-therapy-in-children-with-functional-constipation-100634208","NCT07536698","Co-supplementation With Bifidobacterium Longum W11 and Colopectin for Maintenance Therapy in Children With Functional Constipation","Efficacy of Co-supplementation With Bifidobacterium Longum W11 and Colopectin in the Maintenance Therapy of Children With Functional Constipation: A Randomized Double-Blind Placebo-Controlled Trial","Inclusion Criteria:\n\n* Children aged 2 to 6 years\n* Diagnosis of functional constipation\n* Receiving maintenance therapy with macrogol for at least 3 months\n* Candidates for weaning from macrogol therapy\n\nExclusion Criteria:\n\n* Children with intestinal meteorism or flatulence\n* Children diagnosed with organic constipation\n* History of previous abdominal surgery\n* Children with frailty or disabilities\n* Presence of other organ diseases or syndromes","2 Years","6 Years",{"count":75,"type":21},100,[24],"Functional constipation is a common condition in children and often requires prolonged maintenance treatment with macrogol. This randomized, double-blind, placebo-controlled trial will evaluate whether co-supplementation with Bifidobacterium longum W11 and Colopectin can support maintenance therapy in children with functional constipation who are receiving macrogol and are candidates for weaning. Participants aged 2 to 6 years will be randomized to receive either the active supplementation or placebo once daily for 4 weeks, followed by 4 weeks of follow-up after treatment discontinuation. The study will assess persistence of constipation after macrogol discontinuation, as well as stool consistency, distress during evacuation, soiling episodes, and treatment compliance.",[79],"Functional Constipation","2026-04-15",{"date":82,"type":32},"2026-04-17",{"date":84,"type":21},"2026-04-20",{"date":86,"type":21},"2027-05-17",{"name":38,"class":39},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100632894","effect-of-escherichia-coli-5c-colipral-on-post-colonoscopy-gastrointestinal-symptoms-100632894","NCT07519616","Effect of Escherichia Coli 5C (Colipral®) on Post-Colonoscopy Gastrointestinal Symptoms","Evaluation of the Effectiveness of Escherichia Coli 5C in the Management of Post-Colonoscopy Symptoms: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Complete diagnostic colonoscopy with achievement of the cecal fundus\n* Accepted written informed consent for study participation obtained prior to the start of the study\n\nExclusion Criteria:\n\n* Chronic inflammatory bowel disease\n* Complicated Diverticular Disease (DICA \\>3)\n* Suspected or known colorectal malignancy on index colonoscopy\n* Diagnosed microscopic colitis\n* Operative colonoscopy\n* Severe chronic gastrointestinal symptoms judged by the investigator to interfere with the evaluation of study endpoints\n* Subjects who are immunosuppressed or on systemic immunosuppressive treatment, including patients with primary or acquired immunodeficiency, oncological disease on active treatment with chemotherapy\u002Fimmunotherapy, or autoimmune diseases on immunosuppressive treatment\n* Taking probiotics, prebiotics, or synbiotics within 2-4 weeks prior to enrollment\n* Antibiotic therapy within 4 weeks prior to enrollment\n* Lack of acceptance of written informed consent","80 Years",{"count":97,"type":21},160,[24],"This prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of Escherichia coli 5C (Colipral®) in adult patients undergoing diagnostic colonoscopy. Participants will be randomized in a 1:1 ratio to receive either Colipral® or placebo for 14 days immediately after colonoscopy. The study aims to determine whether Colipral® reduces post-colonoscopy gastrointestinal symptoms compared with placebo, using validated symptom and stool assessment tools, patient-reported global improvement, and safety monitoring.",[101],"Post-Colonoscopy Gastrointestinal Symptoms","2026-04-02",{"date":104,"type":32},"2026-04-09",{"date":106,"type":21},"2026-04-27",{"date":108,"type":21},"2026-10-30",{"name":38,"class":39},1,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":18,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":110},"100631601","effect-of-neurofast-supplementation-on-anxiety-and-cardiovascular-outcomes-in-the-psycho-cardio-phenotype-adults-100631601","NCT07502807","Effect of Neurofast® Supplementation on Anxiety and Cardiovascular Outcomes in the Psycho-Cardio Phenotype Adults","Effect of Neurofast® Supplementation on Anxiety and Cardiovascular Outcomes in the Psycho-Cardio Phenotype: A Prospective Real-World Interventional Observational Study","Inclusion Criteria:\n\n* Age 18-70 years (both sexes)\n* GAD-7 ≥ 5 and\u002For elevated CAQ score\n* PHQ-9 \\\u003C 20\n* Stable clinical status (either no cardiovascular disease or stable cardiovascular disease)\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Severe chronic kidney disease (eGFR \\\u003C 50 ml\u002Fmin)\n* Severe hepatic impairment\n* Psychotic disorders, bipolar disorder, or acute major depression\n* Unstable psychiatric or pharmacological treatment (\\\u003C3 months)\n* Pregnancy or breastfeeding\n* Known allergy or intolerance to investigational treatments (if applicable)",{"count":119,"type":21},80,[24],"This study aims to evaluate anxiety and cardiovascular outcomes in individuals with the psycho-cardio phenotype, characterized by clinically relevant anxiety symptoms with or without established cardiovascular disease (CVD). The study will be conducted as a prospective, real-world interventional study over 12 weeks.\n\nParticipants will be allocated to either a group receiving Neurofast® supplementation (2 tablets per day) or a control group receiving no additional treatment. Psychological assessments will include the Generalized Anxiety Disorder Scale (GAD-7), Patient Health Questionnaire (PHQ-9), and Cardiac Anxiety Questionnaire (CAQ). Cardiovascular parameters, including heart rate, blood pressure, and electrocardiographic (ECG) measures, will also be evaluated.\n\nThe primary objective is to assess changes in anxiety symptoms and heart rate over 12 weeks. Secondary objectives include evaluation of depressive symptoms, cardiovascular parameters, and treatment adherence in a real-world clinical setting.",[123,124],"Anxiety","Cardiovascular Diseases","2026-03-27",{"date":127,"type":32},"2026-03-31",{"date":129,"type":21},"2026-04-07",{"date":131,"type":21},"2027-01-31",{"name":38,"class":39},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":110},"100630946","efficacy-of-nigella-sativa-nisatol-in-women-with-borderline-blood-pressure-values-or-a-non-dipper-blood-pressure-phenotype-100630946","NCT07494279","Efficacy of Nigella Sativa (Nisatol®) in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phenotype","Efficacy of Nigella Sativa (Nisatol®) Supplementation in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phenotype: A Randomized Placebo-Controlled Study With Dietary Intervention Phase","Inclusion Criteria\n\n* Female participants\n* High-normal blood pressure values (≥130\u002F85 mmHg) or mild hypertension (140\u002F90 mmHg) with low cardiovascular risk and no current indication for pharmacological therapy\n* Presence of a non-dipper blood pressure phenotype on 24-hour ambulatory blood pressure monitoring\n* Absence of antihypertensive pharmacological treatment Exclusion Criteria\n* History of cardiovascular disease\n* Diabetes mellitus\n* Severe chronic diseases\n* Use of medications affecting blood pressure or heart rate\n* Known allergy to Nigella sativa or fennel",{"count":141,"type":21},106,[24],"This randomized placebo-controlled study evaluates the efficacy of Nigella sativa (Nisatol®) supplementation in women with borderline blood pressure values or a non-dipper blood pressure phenotype. The study aims to assess the effects of supplementation on blood pressure and resting heart rate in women presenting high-normal blood pressure values (≥130\u002F85 mmHg) and\u002For a nocturnal non-dipper blood pressure pattern.\n\nParticipants will be randomly assigned to receive either Nigella sativa (Nisatol®) or placebo for 12 weeks. After the treatment phase, a washout period will be followed by a dietary intervention phase combined with alternate treatment according to the study design. Cardiological and nutritional assessments will be performed at predefined time points.",[145,146],"Prehypertension","Hypertension","2026-03-20",{"date":125,"type":32},{"date":150,"type":21},"2026-03-30",{"date":152,"type":21},"2026-12-31",{"name":38,"class":39},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":110},"100629450","evaluation-of-the-ability-of-lactobacillus-crispatus-crp21-to-reduce-the-incidence-of-recurrent-bacterial-vaginosis-100629450","NCT07474831","Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis","Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Female participants aged 18 to 45 years\n* Diagnosis of recurrent bacterial vaginosis\n* At least three documented episodes of bacterial vaginosis in the previous 12 months\n* Completion of standard antibiotic therapy for bacterial vaginosis before enrollment\n* Willingness to comply with study procedures and follow-up visits\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Current use of systemic antibiotics or antifungal therapy not related to treatment of bacterial vaginosis\n* Known hypersensitivity to probiotic products or study components\n* Presence of other significant gynecological infections requiring treatment\n* Use of vaginal probiotic products within 30 days prior to enrollment\n* Participation in another clinical trial within the previous 30 days","45 Years",{"count":163,"type":21},156,[24],"Recurrent bacterial vaginosis is a common condition in women of reproductive age and is characterized by a disruption of the normal vaginal microbiota, with a reduction in Lactobacillus species and an overgrowth of anaerobic bacteria such as Gardnerella vaginalis. Recurrence rates after standard antibiotic treatment are high. Lactobacillus crispatus is considered one of the most protective species for maintaining vaginal microbiota balance.\n\nThis multicenter, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the efficacy and safety of a probiotic supplement containing Lactobacillus crispatus CRP21 (Crispavag® capsules) in reducing the incidence of recurrent bacterial vaginosis in women diagnosed with recurrent bacterial vaginosis. After standard antibiotic treatment, participants will be randomly assigned in a 1:1 ratio to receive either the probiotic supplement or a placebo for 12 weeks.\n\nThe primary objective is to evaluate whether supplementation with Lactobacillus crispatus CRP21 reduces the incidence of recurrent bacterial vaginosis episodes compared with placebo. Participants will be followed for a total of 24 weeks, including a 12-week treatment period and a 12-week follow-up period.",[167],"Recurrent Bacterial Vaginosis",{"date":169,"type":32},"2026-03-25",{"date":171,"type":21},"2026-03-23",{"date":173,"type":21},"2027-04-16",{"name":38,"class":39},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":193,"leadSponsor":195,"locationsCount":110},"100628740","berberine-phytosome-for-signs-and-symptoms-of-polycystic-ovary-syndrome-pcos-100628740","NCT07465575","Berberine Phytosome for Signs and Symptoms of Polycystic Ovary Syndrome (PCOS)","Effectiveness of Berberine Phytosome in Improving Signs and Symptoms of Polycystic Ovary Syndrome (PCOS): A Multicentre, Randomized, Controlled Trial","Inclusion Criteria:\n\n* Women aged 18-40 years\n* Diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam criteria\n* Body mass index (BMI) ≥ 25 kg\u002Fm²\n* Evidence of insulin resistance (HOMA-IR above normal range)\n* Willingness to follow lifestyle recommendations including dietary advice and physical activity\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Use of insulin-sensitizing drugs (e.g., metformin) within the previous 3 months\n* Current hormonal therapy including oral contraceptives or anti-androgens\n* Diagnosis of diabetes mellitus\n* Known liver, renal, cardiovascular, or endocrine diseases other than PCOS\n* Use of berberine-containing supplements within the previous 3 months\n* Known hypersensitivity to berberine or related compounds","40 Years",{"count":184,"type":21},150,[24],"This multicenter, randomized, controlled clinical trial aims to evaluate the effectiveness of berberine phytosome supplementation in improving signs and symptoms associated with polycystic ovary syndrome (PCOS). Women presenting with clinical features suggestive of PCOS, including hirsutism, acne, menstrual irregularities, and overweight, will be enrolled.\n\nParticipants will be randomly assigned to one of three groups: (1) berberine phytosome supplementation in women not previously taking inositol, (2) berberine phytosome supplementation in women already taking inositol for at least three months, or (3) a control group receiving lifestyle advice without supplementation. The intervention will consist of berberine phytosome 550 mg once daily for 12 weeks.\n\nThe study will evaluate changes in clinical manifestations associated with hyperandrogenism and metabolic dysfunction, including hirsutism, acne severity, body mass index, and metabolic parameters. The results will provide evidence on the potential role of berberine phytosome supplementation in improving clinical manifestations related to PCOS.",[188],"Polycystic Ovary Syndrome","2026-03-16",{"date":191,"type":32},"2026-03-19",{"date":189,"type":21},{"date":194,"type":21},"2027-03-31",{"name":38,"class":39},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":47,"minAge":203,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":4},"100610966","evaluation-of-the-use-of-a-probiotic-containing-bifidobacterium-breve-prl2020-in-oral-drops-in-preventing-side-effects-from-amoxicillin-or-amoxicillinclavulanic-acid-antibiotic-use-100610966","NCT07234448","Evaluation of the Use of a Probiotic Containing Bifidobacterium Breve PRL2020 in Oral Drops in Preventing Side Effects From Amoxicillin or Amoxicillin\u002FClavulanic Acid Antibiotic Use","Evaluation of the Use of a Probiotic Containing Bifidobacterium Breve PRL2020 in Oral Drops in Preventing Side Effects From Amoxicillin or Amoxicillin\u002FClavulanic Acid Antibiotic Use: a Multicentre, Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n* Male and female participants aged 0-12 years.\n* Undergoing antibiotic therapy with amoxicillin or amoxicillin\u002Fclavulanic acid.\n* Parent or legal guardian provides written informed consent.\n\nExclusion Criteria:\n\n* Use of antibiotic therapy within 4 weeks prior to enrolment.\n* Use of other probiotic products or lactic acid bacteria during the study.\n* Pre-existing diarrhea within 4 weeks prior to enrolment.\n* Chronic inflammatory bowel disease.\n* Immunodeficiency.\n* Lack of parental or legal guardian consent to participate in the study.","0 Years","12 Years",{"count":206,"type":21},1000,[24],"This multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of the probiotic Bifidobacterium breve PRL2020 (Brevicillin® gocce) in preventing gastrointestinal side effects associated with antibiotic therapy using amoxicillin or amoxicillin\u002Fclavulanic acid in pediatric patients aged 0-12 years. Participants will be randomized 1:1 to receive either the probiotic supplement or placebo during standard antibiotic treatment for 6-10 days, followed by a post-treatment observation period up to day 15 without probiotic or placebo administration. The primary objective is to assess the reduction in the incidence of antibiotic-associated diarrhea (AAD).",[210],"Antibiotic-associated Diarrhea","2025-11-19",{"date":213,"type":32},"2025-11-24",{"date":215,"type":21},"2025-12-01",{"date":217,"type":21},"2026-05-29",{"name":38,"class":39},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":47,"minAge":226,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":234,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":110},"100611072","evaluation-of-the-efficacy-of-streptococcus-salivarius-evol12-in-the-reduction-of-recurrent-adenotonsillitis-in-children-100611072","NCT07235826","Evaluation of the Efficacy of Streptococcus Salivarius Evol12® in the Reduction of Recurrent Adenotonsillitis in Children","Evaluation of the Efficacy of Streptococcus Salivarius Evol12® in the Reduction of Recurrent Adenotonsillitis in Children: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Cross-over Clinical Trial","Inclusion Criteria:\n\n* Male and female children aged 3 to 11 years.\n* History of ≥3 documented episodes of acute adenotonsillitis within the previous 12 months, each characterized by fever ≥38°C.\n* Signed and accepted informed consent from a parent or legal guardian.\n\nExclusion Criteria:\n\n* Total obstruction of the nasal cavities.\n* Uncontrolled gastroesophageal reflux disease.\n* Unilateral tonsillar enlargement.\n* Previous tonsil reduction surgery.\n* Lack of parental or legal guardian consent to participate in the study.","3 Years","11 Years",{"count":229,"type":21},200,[24],"This prospective, multicenter, randomized, double-blind, placebo-controlled, cross-over clinical trial will evaluate the efficacy and safety of Streptococcus salivarius Evol12® (Bactoblis® Evol) in reducing the recurrence and duration of acute febrile adenotonsillitis in children aged 3 to 11 years. Participants will receive either the probiotic or a matching placebo for 3 months, followed by a 7-day wash-out and a second 3-month treatment period with the alternative product. The study will assess changes in the incidence and duration of adenotonsillar episodes, antibiotic use, school absences, and sleep quality.",[233],"Recurrent Tonsillitis","RECRUITING","2025-11-17",{"date":211,"type":32},{"date":238,"type":32},"2025-09-01",{"date":240,"type":21},"2026-06-30",{"name":38,"class":39},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":250,"sex":47,"minAge":4,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":252,"phases":4,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":234,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":262,"locationsCount":110},"100602332","evaluation-of-saliva-as-liquid-biopsy-for-early-detection-of-oral-cancer-in-patients-with-oral-submucous-fibrosis-osmf-100602332","NCT07122128","EVALUATION OF SALIVA AS LIQUID BIOPSY FOR EARLY DETECTION OF ORAL CANCER IN PATIENTS WITH ORAL-SUBMUCOUS FIBROSIS (OSMF)","Saliva as Early Detection Tool for Oral Cancer","Sal","Inclusion Criteria:\n\n* healthy volunteers\n* patients with oral submucous fibrosis\n* patients with biopsy proven oral cancer\n\nExclusion Criteria:\n\n* patients with oral infection",true,{"count":206,"type":21},"OBSERVATIONAL","Oral cancer is the top cancer in Pakistan, accounting for 27%, and it has a high mortality rate due to late-stage diagnosis. It primarily affects the lips, tongue, cheeks, and floor of the mouth. Major risk factor for oral cancer development is pan supari chhaliya chewing.\n\nPatients often develop a pre-malignant condition, oral submucous fibrosis, resulting in limited mouth opening. Thus, patients are diagnosed at an advanced level and poor survival. Therefore, saliva appears a potential mode of evaluation for early detection. This project aims to evaluate salivary cells, genes and biochemistry of the saliva among health volunteers and compare it with that of the patients with oral submucous fibrosis and oral cancer.",[255],"The Study Focuses on the Saliva as Potential Source of Early Detection of Oral Cancer","2025-08-07",{"date":258,"type":32},"2025-08-14",{"date":260,"type":32},"2021-06-01",{"date":240,"type":21},{"name":38,"class":39},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":270,"targetDuration":272,"studyType":252,"phases":4,"briefSummary":273,"conditions":274,"keywords":278,"overallStatus":234,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":110},"100579922","study-of-molecular-characterisation-of-early-operable-primary-breast-cancer-in-pakistani-population-100579922","NCT06830590","Study of Molecular Characterisation of Early Operable Primary Breast Cancer in Pakistani Population","BrCa","Inclusion Criteria:\n\n* Women with confirmed diagnosis of breast cancer without history of taking neoadjuvant therapy Good quality tumour samples available for IHC\n\nExclusion Criteria:\n\n* patients received pre-operative chemotherapy or radiotherapy",{"count":271,"type":21},300,"10 Years","This study is looking at the biological characteristics of early operable primary breast cancer in Pakistani Population by using IHC",[275,276,277],"Breast Cancer","Molecular Pathway Deregulation","Treatment",[279,280],"Breast cancer","Molecular characterisation",{"date":282,"type":32},"2025-08-13",{"date":284,"type":32},"2016-02-01",{"date":286,"type":21},"2025-12-31",{"name":38,"class":39},{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":47,"minAge":226,"maxAge":204,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":307,"locationsCount":110},"100581469","evaluation-of-bifidobacterium-breve-prl2020-in-preventing-antibiotic-associated-side-effects-from-amoxicillin-or-amoxicillinclavulanic-acid-100581469","NCT06850714","Evaluation of Bifidobacterium Breve PRL2020 in Preventing Antibiotic-Associated Side Effects From Amoxicillin or Amoxicillin\u002FClavulanic Acid","Evaluation of the Use of Bifidobacterium Breve PRL2020 in Preventing Side Effects From Amoxicillin or Amoxicillin\u002FClavulanic Acid Antibiotic Use: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 3 to 12 years\n* Requiring antibiotic therapy with Amoxicillin or Amoxicillin\u002FClavulanic Acid\n* Ability to comply with the study protocol (parents\u002Fcaregivers must complete symptom diaries)\n\nExclusion Criteria:\n\n* Use of any antibiotic therapy within 3 months before study enrollment\n* Known gastrointestinal diseases (e.g., inflammatory bowel disease, celiac disease)\n* History of chronic diarrhea or constipation\n* Allergy to probiotics or study interventions\n* Any immunocompromised state",{"count":296,"type":21},800,[24],"This study aims to evaluate the efficacy and safety of the probiotic Bifidobacterium breve PRL2020 in preventing gastrointestinal and extra-intestinal side effects caused by Amoxicillin or Amoxicillin\u002FClavulanic Acid in pediatric patients. The study will compare a treatment group receiving the probiotic alongside antibiotics with a control group receiving antibiotics alone. The primary focus is on reducing antibiotic-induced intestinal discomfort through microbiota modulation.",[300],"Antibiotic Side Effect","2025-02-27",{"date":303,"type":32},"2025-03-04",{"date":305,"type":21},"2025-02-23",{"date":286,"type":21},{"name":38,"class":39},""]